Surface phenotype of antileukemia CTL lines
| . | Effector cells after primary stimulation . | Effector cells after 4 stimulations . | ||
|---|---|---|---|---|
| % . | (Range) . | % . | (Range) . | |
| CTL lines BMT recipients | ||||
| CD3 | 48 | (42 -57) | 94 | (93 -96) |
| CD8 | 45 | (32 -55) | 82 | (73 -88) |
| CD4 | 5 | (4 -6) | 8 | (7 -10) |
| CD56 | 50 | (36 -66) | 14 | (11 -20) |
| γδ | 10 | (5 -14) | 30 | (13 -65) |
| CTL lines* BMT donors | ||||
| CD3 | 66 | (58 -79) | 92 | (87 -97) |
| CD8 | 50 | (41 -62) | 84 | (80 -88) |
| CD4 | 6 | (3 -10) | 11 | (8 -15) |
| CD56 | 28 | (20 -30) | 9 | (6 -15) |
| γδ | 8 | (5 -16) | 21 | (3 -52) |
| . | Effector cells after primary stimulation . | Effector cells after 4 stimulations . | ||
|---|---|---|---|---|
| % . | (Range) . | % . | (Range) . | |
| CTL lines BMT recipients | ||||
| CD3 | 48 | (42 -57) | 94 | (93 -96) |
| CD8 | 45 | (32 -55) | 82 | (73 -88) |
| CD4 | 5 | (4 -6) | 8 | (7 -10) |
| CD56 | 50 | (36 -66) | 14 | (11 -20) |
| γδ | 10 | (5 -14) | 30 | (13 -65) |
| CTL lines* BMT donors | ||||
| CD3 | 66 | (58 -79) | 92 | (87 -97) |
| CD8 | 50 | (41 -62) | 84 | (80 -88) |
| CD4 | 6 | (3 -10) | 11 | (8 -15) |
| CD56 | 28 | (20 -30) | 9 | (6 -15) |
| γδ | 8 | (5 -16) | 21 | (3 -52) |
Obtained from PBMCs.